A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer

Inclusion Criteria:

·≥ 18 years old;

* Diagnosed as unresectable hepatocellular carcinoma through histopathological and/or cytological examination, or meeting the clinical diagnostic criteria for hepatocellular carcinoma in the 2022 edition of the guidelines for the diagnosis and treatment of primary liver cancer;
* CNLC liver cancer stage III;
* Liver function Child Pugh A or B grade 7 points;
* Has not received systematic treatment in the past;
* Patients with active HBV infection who meet one of the following conditions can be enrolled: ① Within 28 days before enrollment, the patient's HBV DNA is less than 500 IU/mL. If they have received anti HBV treatment, they need to continue their original antiviral treatment; If anti HBV treatment has not been received, it is necessary to receive anti HBV treatment throughout the entire course of medication (according to local treatment standards; for example, entecavir); ② For patients with HBV DNA\>500 IU/mL and who have not received antiviral therapy, they must receive at least 7 days of antiviral therapy (according to local treatment standards; for example, entecavir) before enrollment in this study, and are willing to continue receiving antiviral therapy during the study. Before enrollment, the serum HBV-DNA virus should be retested to decrease by more than 1 log value For patients with HBV DNA\>500 IU/mL and who have received antiviral therapy, they must receive at least 7 days of antiviral therapy (according to local treatment standards; for example, entecavir) before enrollment in this study, and are willing to continue receiving antiviral therapy during the study. Serum HBV-DNA virus levels should be retested before enrollment;
* Active HCV infected individuals with stable disease status after treatment;
* At least one tumor lesion available for evaluation;
* Clear consciousness, language expression ability or reading ability, able to communicate normally, and cooperate to complete the questionnaire evaluation;
* Voluntarily join this study and sign an informed consent form.

Exclusion Criteria:

* Simultaneously having two or more active primary malignant tumors;
* Portal vein cancer thrombus invades the superior mesenteric vein;
* Received radiation therapy within the past 4 weeks;
* Expected survival time is less than 3 months;
* Pregnant or lactating women or those planning to conceive;
* Coagulation dysfunction (INR\>2.0, PT\>16 s) or diseases with a strong likelihood of bleeding (including but not limited to esophageal and/or gastric variceal bleeding, active ulcers, uncontrolled hypertension);
* Refusing to cooperate with follow-up visits;
* Other reasons led the researchers to believe that it was not suitable to participate in this study.